Skip to content Skip to footer
Smart Glasses, Lunar Logistics and Simpler Diabetes Care Offer a Compelling Growth Theme Wall Street’s most interesting growth stories do not always share an industry. Sometimes they share a commercial breakthrough: making something difficult easier to buy, use or deliver. Warby Parker…
Healthcare’s most compelling growth stories often begin with an unglamorous proposition: make an existing problem less difficult to manage. For INOVIO Pharmaceuticals (NASDAQ: INO), that means a newly approved immunotherapy intended to reduce repeated surgeries. For IDEXX Laboratories (NASDAQ: IDXX), it means…
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has delivered the kind of Phase 3 result biotechnology investors wait patiently—and, on occasion, not so patiently—for. The company reported that avexitide reduced the composite rate of severe and clinically meaningful post-bariatric hypoglycemia events by 55% versus…